Paper Details

  1. Home
  2. Paper Details

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Author: AkersRobin, ArnaudClaude D, BjarnasonNina H, CransGerald, DraperMichael W, JohnstonC Conrad, JollyElaine E, MasonTimothy M, NevenPatrick, PlouffeLeo, WattsSteven D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the long-term effects of raloxifene in postmenopausal women. The results showed that raloxifene treatment for 5 years effectively reduced the risk of osteoporosis and had no significant adverse effects on the endometrium or vaginal bleeding.
Paper Details　
Original Abstract of the Article :
Raloxifene hydrochloride (60 mg/day) is a selective estrogen receptor modulator indicated for the prevention and treatment of postmenopausal osteoporosis. Raloxifene treatment for 3 years increases bone mineral density (BMD) and, unlike tamoxifen (a triphenylethylene selective estrogen receptor modu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12851517

データ提供：米国国立医学図書館（NLM）

Raloxifene: A Journey Through the Desert of Menopause

This study explores the effects of raloxifene, a selective estrogen receptor modulator, in postmenopausal women. It's like a camel caravan traversing the desert of menopause, searching for ways to maintain health and well-being. Raloxifene is primarily used for preventing and treating osteoporosis, a condition that weakens bones, making them more prone to fractures. The study investigated the long-term effects of raloxifene, specifically its impact on bone mineral density and the endometrium, the lining of the uterus. It’s like a camel caravan stopping at different oases along the way, assessing the impact of the journey on both the caravan and the surrounding environment.

The Benefits of Raloxifene for Bone Health

The study found that raloxifene, when taken for 5 years, significantly increased bone mineral density, protecting women from the debilitating effects of osteoporosis. It’s like finding a source of water in the desert, strengthening the caravan and allowing it to continue its journey. The authors also confirmed that raloxifene did not stimulate the endometrium, unlike other similar drugs. It’s like a camel caravan that leaves no trace behind, respecting the natural balance of the desert.

Navigating the Desert of Menopause with Confidence

This study offers valuable insights for postmenopausal women. Raloxifene provides a safe and effective way to maintain bone health while minimizing the risk of endometrial complications. It’s like having a reliable guide on the desert journey, offering protection and reassurance along the way. The study encourages women to discuss their individual needs and concerns with their healthcare providers to make informed decisions about their health and well-being.

Dr. Camel's Conclusion

This study reminds us that the journey through menopause can be smoother with the right tools and support. It's like a camel caravan navigating the desert, with the right provisions and guidance, we can find a safe and fulfilling path.

Date :
  1. Date Completed 2003-10-07
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

12851517

DOI: Digital Object Identifier

00042192-200310040-00011

Related Literature

Article Analysis
・Effects of raloxifene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.